CME: Acquired Resistance to Targeted Therapy of NSCLC: A Global Perspective

Acquired Resistance to Targeted Therapy of NSCLC: A Global Perspective

Acquired Resistance to Targeted Therapy of NSCLC: A Global Perspective
RestartResume

Join the discussion on the dysregulation of the MET pathway in non-small cell lung cancer.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    EGFR tyrosine kinase inhibitors, or EGFR-TKIs, have resulted in dramatic improvements for patients with EGFR-mutant advanced non-small cell lung cancer. However, acquired resistance continues to limit their long-term benefit. While often due to an acquired T790M mutation, dysregulation of the MET pathway in non-small cell lung cancer is emerging as an important participant in acquired EGFR-TKI resistance. Join us as we discuss the dysregulation of the MET pathway in non-small cell lung cancer, as well as the therapeutic potential of MET pathway inhibitors.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    D. Ross Camidge, MD, PhD
    Director, Thoracic Oncology
    University of Colorado
    Aurora, CO

    Consulting Fees: AbbVie, EMD Serono

    Faculty:
    Luis Paz-Ares, MD, PhD
    Chair, Medical Oncology Department
    Hospital Doce de Octubre
    Associate Professor
    Universidad Complutense
    Madrid, Spain 

    Advisory Board: Genómica
    Ownership Interest: Altum Sequencing
    Consulting Fees: Adacap, Amgen, AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Incyte, Ipsen, Lilly, Merck, MSD, Novartis, Pfizer, Pharmamar, Roche, Servier, Sysmex, Sanofi
    Research Grants: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Differentiate between the various classes and mechanisms of action of approved and investigational MET inhibitors.
    • Assess clinical evidence on the utility of MET pathway inhibition as monotherapy or in combination with other agents in patients with NSCLC, including those experiencing resistance to EGFR-TKI therapy.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, and other healthcare professionals that manage patients with NSCLC.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Agile. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Agile you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”.  

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free